Clinical Trial Update: Safety and Efficacy Study of PTG-100 in the Treatment of Moderate to Severe Ulcerative Colitis [Phase 2]

View source ↗

Summary

Phase 2 safety and efficacy study of PTG-100 for moderate to severe ulcerative colitis was terminated, and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• PTG-100

Snippet

Sponsor: Protagonist Therapeutics, Inc. | Conditions: Ulcerative Colitis | Phase 2 | Status: TERMINATED | Results posted: 2021-03-22